Neogen Chemicals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nxdxdbryoin5er4rj6ssc4l7.pdf

Key Takeaways


Battery Chemicals: Customer Pipeline & Qualification

Dr. Harin Kanani: "most of them were of the opinion that the approval cycle in Pakhajan will be shorter because our testing method, raw material supply, manufacturing, all of this is already aligned. Only just the site is changing."

Project Timelines, Capex & Funding


Revenue Guidance & Segment Outlook

SegmentFY27 GuidanceFY28 OutlookFY29 Outlook
Standalone (base business)₹875–950 crore; original ₹950–1,000 crore still achievable if organolithium and lithium sales outperform~₹1,100 crore at full utilization with optimization₹1,200–1,250 crore
Battery chemicals (Neogen Ionics)₹300 crore+; majority in H2; sequential quarterly increases expected₹1,200–1,400 crore; more clarity in H2 FY27₹2,500–2,900 crore
Consolidated——₹3,700–4,200 crore
Dr. Harin Kanani: "If we are able to outperform in that, then we would be able to even achieve the original INR 950 crore to INR 1,000 crore. But because there was a slight delay in starting the Dahej plant, that is why we said INR 875 crore to INR 950 crore."

Q4 Performance: Volume-Led Growth with Margin Resilience


Organolithium & Intermediate Salt Opportunities

Dr. Harin Kanani: "Morita being our partner, they are positively considering to purchase this from us and other established LiPF6 producers are also considering to buy this intermediate from us to achieve the China-free requirement."

Commodity Prices & Competitive Position

Dr. Harin Kanani: "I normally do not factor in commodity price increase into how it will change our topline significantly because most of it is a pass-through and it is anyway something which is difficult to predict."

Guidance & Commitments

CommitmentSpecificsTimeline
Dahej replacement plant commissioningCommercial supply startJuly–August 2026
Dahej Phase 1 completionFull 2,500 MT plus 500 MT intermediate capacityQ3 FY27 (some capacity possibly Q4)
Pakhajan Phase 2 completionElectrolyte H1, salt H2; mostly ready by end Q3March 2027 (SCOD approved)
FY27 standalone revenue₹875–950 crore (original ₹950–1,000 crore achievable if organolithium/lithium outperform)FY27
FY27 battery chemicals revenue₹300 crore+; majority in H2FY27
FY28 battery chemicals revenue₹1,200–1,400 croreFY28
FY29 consolidated revenue₹3,700–4,200 croreFY29
ROCE on battery materials18–20% even after revised capexAt stabilization
Peak debt₹1,700 crore (unchanged despite capex increase)Through project completion
Morita JV equity contribution$20 millionH1 FY27
Organolithium capacity utilization80–90% of increased 300 MT capacityFY27
Second domestic customer pilot lineStart pilot productionQ2 FY27
Second domestic customer commercial productionMega-scale volumes2027

Key Metrics

MetricQ4 FY26
Consolidated revenue₹247 cr, +22% YoY
Consolidated EBITDA₹44 cr, +21% YoY
Consolidated EBITDA margin17.8%, sustained despite expansion overheads and supply chain disruptions
Consolidated PAT₹11 cr
Organic Chemicals revenue₹194 cr, +7% YoY
Inorganic Chemicals revenue₹53 cr, +145% YoY
Neogen Ionics revenue₹13 cr (Q4), ₹36 cr (full year FY26)
FY27 standalone revenue guidance₹875 cr to ₹950 cr, non-battery business
FY27 battery chemicals revenue guidance₹300 cr plus, majority in H2 FY27
Dahej Phase 1 project budget₹428 cr, completion by February 2027
Pakhajan Phase 2 revised cost₹1,367 cr, expected completion by March 2027
Consolidated total debt₹1,330 cr; net debt ₹1,295 cr
Cumulative on-account insurance claims received₹140 cr plus salvage realization of ₹7 cr; net claim receivable ₹203 cr
Promoter capital infusion₹161 cr through preferential allotment
Morita planned equity contribution$20 million towards JV, expected H1 FY27